A Novel Role for the RNA–Binding Protein FXR1P in Myoblasts Cell-Cycle Progression by Modulating p21/Cdkn1a/Cip1/Waf1 mRNA Stability

Laetitia Davidovic1,2, Nelly Durand1,2, Olfa Khalfallah1,2, Ricardo Tabet3, Pascal Barbry1,2, Bernard Mari1,2, Sabrina Sacconi4, Hervé Moine3, Barbara Bardoni1,2*

1 Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR 7275, Valbonne, France, 2 Université de Nice-Sophia Antipolis, Nice, France, 3 IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), CNRS, UMR7104, Inserm U596, Collège de France, Strasbourg University, Illkirch-Graffenstaden, France, 4 INSERM U638, Faculté de Médecine, Université de Nice Sophia-Antipolis, Centre de Référence pour les Maladies Neuromusculaires, CHU de Nice, Nice, France

Abstract

The Fragile X-Related 1 gene (FXR1) is a paralog of the Fragile X Mental Retardation 1 gene (FMR1), whose absence causes the Fragile X syndrome, the most common form of inherited intellectual disability. FXR1P plays an important role in normal muscular development, and its absence causes muscular abnormalities in mice, frog, and zebrafish. Seven alternatively spliced FXR1 transcripts have been identified and two of them are skeletal muscle-specific. A reduction of these isoforms is found in myoblasts from Facio-Scapulo Humeral Dystrophy (FSHD) patients. FXR1P is an RNA–binding protein involved in translational control; however, so far, no mRNA target of FXR1P has been linked to the drastic muscular phenotypes caused by its absence. In this study, gene expression profiling of C2C12 myoblasts reveals that transcripts involved in cell cycle and muscular development pathways are modulated by Fxr1-depletion. We observed an increase of p21—a regulator of cell-cycle progression—in Fxr1-depleted mouse C2C12 and FSHD human myoblasts. Rescue of this molecular phenotype is possible by re-expressing human FXR1P in Fxr1-depleted C2C12 cells. FXR1P muscle-specific isoforms bind p21 mRNA via direct interaction with a conserved G-quadruplex located in its 3’ untranslated region. The FXR1P/G-quadruplex complex reduces the half-life of p21 mRNA. In the absence of FXR1P, the upregulation of p21 mRNA determines the elevated level of its protein product that affects cell-cycle progression inducing a premature cell-cycle exit and generating a pool of cells blocked at G0. Our study describes a novel role of FXR1P that has crucial implications for the understanding of its role during myogenesis and muscle development, since we show here that in its absence a reduced number of myoblasts will be available for muscle formation/regeneration, shedding new light into the pathophysiology of FSHD.

Introduction

The Fragile X-Related 1 (FXR1) gene belongs to a small gene family that includes the Fragile X Mental Retardation 1 (FMR1) and Fragile X-Related 2 (FXR2) genes (reviewed in [1]). Human FMR1 is located on chromosome Xq27.3 [2] and inactivation of FMR1 expression leads to the Fragile X syndrome in human, the first cause of inherited mental retardation [5]. FXR1 and FXR2 are autosomal genes, respectively mapping at 3q28 and 17p13.1 [3,4]. The FXR1 gene is highly expressed in muscle and its pre-mRNA is known to undergo extensive alternative splicing, which generates distinct FXR1 mRNA variants that produce FXR1P isoforms with divergent C-terminal regions [6,7]. Four isoforms ranging from 70 to 80 KDa (Isoa, Isob, Isoe, Isof) are ubiquitously expressed, including in murine [7,8] and human myoblasts [9]. Myoblasts also express long muscle-specific FXR1 mRNA variants, termed Isoc and Isof, which are massively induced upon muscular differentiation [7,8,9,10]. Importantly, these muscle-specific mRNA variants of FXR1 are the only expressed in adult muscle [6,7,8,9,11]. Defects in FXR1 gene muscular pattern of expression have been observed in patients affected by Facio-Scapulo Humeral Dystrophy (FSHD), the most prevalent muscular dystrophy affecting adults and children [9]. Similar defects were observed in a mouse model of myotonic dystrophy (DM1, [12]). As a result, the long isoforms FXR1P Isoc and Isof of 82–84 kDa are depleted in myopathic muscle. Consistent with these altered expression pattern of FXR1 in myopathic patients, Fxr1-knockout mouse die shortly after birth most likely due to an abnormal development of cardiac and respiratory muscles [13]. A mouse model with reduced levels of Fxr1 expression has also been generated, and displays reduced limb musculature and a shorter life span of about 18 weeks [13]. Moreover, during Xenopus embryogenesis, complete or partial inactivation of Fxr1 disrupts somitic myotomal cell rotation and segmentation, impeding normal myogenesis [14].
Author Summary

Muscle development is a complex process controlled by the timely expression of genes encoding crucial regulators of the muscle cell precursors called myoblasts. We know from previous studies that inactivation of the Fragile X related 1 (FXR1) gene in various animal models (mouse, frog, and zebrafish) causes muscular and cardiac abnormalities. Also, FXR1P is reduced in a human myopathy called Fascio-Scapulo Humeral Dystrophy (FSHD), suggesting its critical role in muscle that findings presented in this study contribute to elucidating. Cell-cycle arrest is a prerequisite to differentiation of myoblasts into mature myotubes, which will form the muscle. One key regulator is the p21/Cdkn1a/Cip1/Waf1 protein, which commands myoblasts to stop proliferating, and this action is particularly important during muscle regeneration. In this study, we have identified FXR1P as a novel regulator of p21 expression. We show that FXR1P absence in mouse myoblasts and FSHD-derived myopathic myoblasts increases abnormally the levels of p21, causing a premature cell cycle exit of myoblasts. Our study predicts that FXR1P absence leads to a reduced number of myoblasts available for muscle formation and regeneration. This explains the drastic effects of FXR1 inactivation on muscle and brings a better understanding of the molecular/cellular bases of FSHD.

Finally, depletion of zFxr1p during early development of the zebrafish leads to cardiomyopathy and muscular distrophy [15]. All these data point out an evolutionarily conserved role for FXR1P in myogenesis.

FXR1P contains two KH domains and one RGG box that are characteristic motifs in RNA-binding proteins [4,16]. In addition, FXR1P harbours nuclear localization and export signals (NLS and NES) enabling nucleocytoplasmic shuttling [4,17]. In most cell types and tissues studied, FXR1P isoforms are associated to messenger ribonucleoparticles (mRNPs) present on polyribosomes, suggesting a consensus role in translation regulation for FXR1P [18]. However, it was reported that, in undifferentiated myoblasts, FXR1P long isoforms Isoe and Isof are not detected on mRNAs encoding: Semaphorin 7a (Sema7a), the Ca2+-binding multiple C2 domains transmembrane protein 2 (Mctp2), asialoglycoprotein receptor 1 (Asgr1), the cyclin-dependant kinase inhibitor p21 (p21/Cdkn1a/Cip1/Waf1), that is also observed in FSHD-derived myoblasts. In this study, we further explore the role played by the direct interaction of FXR1P with p21 mRNA in the post-transcriptional control of p21 levels.

Results

Inactivation of Fxr1 in C2C12 myoblasts selectively affects the expression of a range of genes associated with cell-cycle regulation during muscle development

To understand the functional role of FXR1P in myoblasts, we used as a cellular model the C2C12 myoblastic cell line. This murine cell line enables to reproduce myogenesis in vitro [23] and expresses all the myogenic factors as well as FXR1P [7,8]. In this model, we inactivated the expression of all FXR1P isoforms by transient transfection of siRNAs targeting exon 14, a constitutive exon present in all Fxr1 mRNAs [6]. As shown in Figure 1A, quantitative RT-PCR performed on C2C12 cells transfected with siFxr1 siRNAs reveals a significant reduction in Fxr1 mRNA as compared to siControl-transfected cells (13.45%±3.4% residual expression, Figure 1A). Knockdown of all isoforms of Fxr1P was obtained by siFxr1 transfection, as shown by western-blot analysis using the 3FX antibody (Figure 1B, [8]). Note that the levels of FXR2P, the close homologue of FXR1P, also recognized by 3FX antibody, remain unaffected, confirming the specificity of the knockdown strategy (asterisk, Figure 1B). In siFxr1-transfected myoblasts, the decrease in epifluorescence signal after FXR1P-immunolabeling as compared to siControl-transfected cells confirms the efficiency of the knockdown (Figure 1C). The knockdown appears to homogeneously affect all the cells since the signal is uniformly decreased. Note that in C2C12 cells, FXR1P immunoreactivity is mainly cytoplasmic, however, signal is also detected in the nucleus (Figure 1C). Indeed, we confirmed the partial nuclear localization of FXR1P in myoblasts by confocal microscopy (Figure 1D), as described previously for the long isoforms of FXR1P in C2C12 myoblasts [7] and in human myoblasts [9].

To determine the impact of the inactivation of Fxr1 on gene expression in myoblasts, total RNA was extracted from siControl and siFxr1-transfected C2C12 myoblasts and simultaneously analysed using whole genome mouse microarrays. Among the genes showing measurable differential levels of expression, a significant change was observed for 105 transcripts (32 down- and 73 up-regulated) of which 79 were annotated in the RefSeq database (Figure 1E and Table S1). As expected, Fxr1 mRNA appears among the most significantly down-regulated in siFxr1-transfected cells (Figure 1E and Table S1). To confirm the observed dysregulation of a subset of mRNAs in Fxr1-knockdown C2C12 myoblasts, we performed quantitative RT-PCR analysis (Figure 1F). Interestingly, in Fxr1-depleted myoblasts, we were able to confirm by quantitative RT-PCR a significant upregulation of mRNAs encoding: Semaphorin 7a (Sema7a), the Ca2+-binding multiple C2 domains transmembrane protein 2 (Mctp2), asialoglycoprotein receptor 1 (Asgr1), the cyclin-dependant kinase inhibitor p21 (p21/Cdkn1a/Cip1/Waf1), Hepatocyte growth factor (Hgf), Dual specific phosphatase (Dusp6) and finally Limb-bud and heart protein (Lbh, Figure 1E). Conversely, we confirmed a significant down-regulation of Cdk15 mRNA encoding the cyclin-dependent kinase 15. Finally, the mRNAs encoding the myoregulatory factors MyoD and Myogenin for which no mRNA variations were detected by microarray analysis remained unaffected (Figure 1F). These analyses were further repeated on C2C12 cells inactivated for Fxr1 by transfection of a different siRNA (siFxr1 #2) targeting premature cell cycle exit of myoblasts. We link this to a robust increase in the levels of the cyclin-dependant inhibitor p21/Cdkn1a/Cip1/Waf1, that is also observed in FSHD-derived myoblasts. In this study, we further explore the role played by
Fxr1 exon 6, another constitutive exon of Fxr1 present in all its variants [6]. This second siRNA leads to a 37% residual expression of Fxr1 mRNA (Figure S1A) and reduces all FXR1P isoforms (Figure S1B) as compared to siControl. In addition, siFxr1#2-mediated knockdown of Fxr1 efficiently modulated the previously studied subset of mRNAs to induce variations similar to the one observed with the first siRNA against Fxr1 (Figure S1C).

Importantly, this cross-analysis using two siRNAs targeting distinct regions of Fxr1 mRNA exclude the fact that the observed variations could derive from off-target effects of the siRNAs.

To gain insights into the pathways perturbed by Fxr1 depletion, we performed an analysis of the biological functions or processes selectively enriched among the altered transcripts, using the Ingenuity Pathway Analysis (IPA) software (Table S2). Interestingly, Fxr1 knockdown in C2C12 myoblasts significantly affected the functional categories ‘cell cycle’ (Table S2), ‘skeletal and muscular system development and function’ and ‘skeletal and muscular disorders’ (Table S2). Importantly enough, a subset of mRNAs perturbed in siFxr1-knockdown myoblasts compared to control repeatedly appeared determinant for the definition of the affected functional categories: the cyclin-dependent kinase (Cdk15),...
the cyclin-dependent kinase inhibitor (p21/Cdkn1a/Cip1/Waf1) and the Hepatocyte growth factor (Hgf).

**Fxr1**-depletion in myoblasts leads to premature exit of cell cycle

One of the most recurrent terms in IPA analysis of dysregulated mRNA upon *Fxr1* depletion were ‘cell cycle progression’, ‘arrest in G0/G1’, ‘proliferation’ and also ‘cell viability’ (Table S2). This prompted us to analyse myoblasts’ viability and proliferation abilities upon *Fxr1*-depletion. Fluorescence-Activated Cell Sorting (FACS) analysis of the DNA intercalant Propidium Iodide (PI) incorporation on living cells allowed us to detect no changes in the overall viability of *Fxr1*-knockdown (92.5% viability) compared to control (90.5% viability) C2C12 cells (Figure 2A). To assess the proliferation ability of *Fxr1*-depleted myoblasts, we conducted tetrazole MTT proliferation assays. Interestingly, after 48 hours in culture, siFxr1-transfected C2C12 cells exhibit a significant 15% decrease in MTT reductase activity as compared to control (Figure 2B). This suggests that *Fxr1* depletion may induce alterations of myoblasts cell cycle. We therefore further analysed the distribution in the various cell cycle phases of siFxr1- or siControl transfected myoblasts. The DNA content of the cells was assessed by FACS-measurement of the amount of PI incorporated in cells. Surprisingly, in a normal asynchronous cell population, we did not observe any significant change in the cell cycle phases distribution of the C2C12 cells transfected with siFxr1 or siControl, in normal growth conditions (Figure 2C).

To highlight specific defects in cell cycle, we synchronized siFxr1- and siControl-transfected myoblasts by treatment with the cell cycle blocker mimosine, that arrests cell cycle progression at the G1/S phase border [24]. Since the effects of this cell cycle blocker are fully reversible, we then allowed the synchronized cells to reenter cell cycle by incubating them in normal growth medium for 16 hrs before FACS analysis. In these conditions, we did observe a significant 27.6% increase in the number of cells in the G0/G1 phase in *Fxr1*-knockdown myoblasts, as compared to control. This increase in the G0/G1 population is accompanied by a 51.9% decrease in the number of cells in the G2/M phase. Importantly, no differences were observed in the proportion of cells in the Sub-G1 phase - corresponding to cellular debris with a lower DNA content liberated by apoptotic cells [25] - in asynchronous cells (Figure 2A) and after release from cell cycle blocker (Figure 2D). These data indicate that FXR1P depletion in myoblasts does not lead to cell viability defects but rather causes a blockade and accumulation of cells in the G0/G1 phase to the detriment of mitosis.

Thus, to determine whether the cells were blocked in G0 or G1, we performed immunolabeling of C2C12 cells in normal growth conditions and quantified the number of DAPI-positive nuclei and the amount of cells positive for the proliferation marker Ki67 (Figure 3). We observed that the number of nuclei in cultures of siFxr1-transfected myoblasts is decreased by 26%, suggesting that *Fxr1* depletion limits the proliferating abilities of myoblasts (Figure 3B). Quantification of cells expressing Ki67 enabled us to detect that siRNA-mediated depletion in *Fxr1* leads to a subtle, but significant 10% decrease in the number of Ki67-positive cells compared to control (Figure 3C). Since Ki67 is expressed during all active phases of the cell cycle (G1, S, G2, and mitosis), but absent from quiescent cells (G0) [26], the unlabeled cells most likely represent resting cells blocked in G0.

The absence of FXR1P in C2C12 cells and in FSHD patients-derived myoblasts affects the levels of endogenous p21 mRNA and protein

The premature cell cycle arrest we observed in *Fxr1*-depleted myoblasts prompted us to examine the subset of deregulated mRNAs identified by microarray analysis in order to identify candidates for regulation by FXR1P that could contribute to explain this phenotype. The most promising mRNA candidate appeared to encode the ubiquitous cyclin-dependent kinase inhibitor (CDKI) p21 –also known as Cdkn1a/Cip1/Waf1– that belongs to the Cip/Kip family of CDKI. In myoblasts, p21 is known to block cell cycle progression to trigger cell-cycle exit, a prerequisite to muscular differentiation [27,28,29].

In *Fxr1*-depleted myoblasts, we found that p21 mRNA level is significantly increased by microarray analysis (Figure 1E, Table S1) and confirmed a 1.76-fold upregulation of the transcript by quantitative-RT PCR in these *Fxr1* loss-of-function experiments (cf Figure 1F). This upregulation of p21 mRNA level in *Fxr1*-depleted myoblasts was further confirmed using a second siRNA targeting *Fxr1* (Figure S1). We had previously shown that the muscle-specific long isoforms of FXR1P, notably Isoe, are depleted in myoblasts derived from Fascio-ScapuloHumeral Distrophy (FSHD) patients and had hypothesized that this could induce deregulation of mRNA targets specific to this isoform FXR1P Isoe [9]. To test this hypothesis on this new potential mRNA target of FXR1P, we assessed the status of human P21 in the same samples used in our previous study. Interestingly enough, P21 mRNA levels are significantly increased in FSHD patients by a 1.8 factor (Figure 4A).

We then sought to verify whether this increase in p21 at the mRNA level was translated at the protein level by western-blotting (WB) analysis. Quantification of WB of siFxr1-transfected C2C12 using the ImageJ software revealed a 1.92 fold increase in p21 protein level (Figure 4B). Concomitantly, we observed by western-blotting that the levels of P21 protein are increased in FSHD myoblasts compared to control by a 1.66 factor (Figure 4C). These data indicate that depletion of FXR1P and particularly of its long muscle-specific isoforms increases p21 mRNA and correlatively increase the levels of p21 protein both in murine and human myoblasts.

To assess the specificity and the direct nature of the effects we observed on p21 mRNA levels by FXR1P loss of function experiments, we first used a gain-of-function approach. For these experiments, we used FXR1P long isoform Isoe since its depletion in FSHD myoblasts recapitulates the effects on p21 mRNA levels of a knockdown of all FXR1P isoforms in C2C12 cells (cf Figure 4). Interestingly, in contrast to *Fxr1* loss-of-function in C2C12 myoblasts, over expression of FXR1P Isoe lead to a 19,1% significant decrease in endogenous p21 mRNA levels as compared to transfection with empty vector (Figure 5A). This ascertains the fact that the effects we observe on p21 mRNA levels are directly related to the levels of FXR1P present in the cell. Secondly, we performed rescue experiments using a pTL1 plasmid bearing FXR1 Isoe cDNA in which we generated by site-directed mutagenesis 4 mismatches to avoid recognition of the transgene by siFxr1. This strategy enabled to efficiently re-express FXR1P Isoe in *Fxr1*-knocked down myoblasts (Figure 5C). Rescue of the expression of FXR1P Isoe lead to a significant reduction in p21 mRNA levels as compared to unrescued myoblasts. The rescue with FXR1P Isoe is total since the levels of p21 mRNA in rescued cells are restored to control levels. Of notice, similar results were obtained using another mutant plasmid of pTL1.Isoe (data not shown), confirming the efficiency of the rescue strategy.
Muscle-Specific FXR1P Isoforms Regulate p21 Levels

A

% viable cells

siControl  siFxr1

B

MTT A585

siControl  siFxr1

C

asynchronous

siControl

siFxr1

D

synchronized

siControl

siFxr1
These data confirm the specificity of our approach and suggest that p21 mRNA may be a target of FXR1P in C2C12 murine myoblasts and in human myoblasts, either directly by RNA-protein physical interaction, or indirectly by modulating a pathway involved in p21 levels controls.

p21 mRNA is a novel mRNA target of FXR1P, both in vitro and in vivo

Murine p21 mRNA is 1910 nts long (GenBank Accession number: GI 161760647), with a very short 5’UTR of less than 100 nts, a 480 nts coding sequence and a 1329 nts long 3’UTR where lie most of the regulatory elements for the stability of this mRNA (Figure 6A). Notably, the ARE located at position 86–103 nts on the 3’UTR is bound by the RNA-binding protein HuR to regulate the stability of the mRNA during muscle differentiation [30]. Given the ability of FXR1P Isoa to bind ARE sequences [19,20], we hypothesized that the ARE present in p21 mRNA could be the binding site of FXR1P.

To test the physical interaction between FXR1P and p21 mRNA and determine the portion of the mRNA involved in the interaction, we performed in vitro filter-binding assays [21] using recombinant FXR1P and radiolabeled fragments of p21 mRNA 3’UTR described in Figure 5A. We chose to use FXR1P Isoe, the longest muscle-specific isoform of FXR1P for binding experiments since i) it was described to have RNA-binding properties [21], ii) its depletion in FSHD myoblasts recapitulates the effect on p21 mRNA levels of a complete knockdown of all FXR1P isoforms in C2C12 cells (cf Figure 4) and iii) Isoe is able to restore p21 mRNA levels to normal in Fxr1-knockdown myoblasts (cf Figure 5). As controls for interaction, we used the N19 fragment of FMR1 mRNA containing a G-quadruplex RNA structure [31], known to be specifically bound by FXR1P Isoe, and its truncated version N19D35 unable to be bound by FXR1P [21]. As expected, FXR1P was able to recognize the G-quadruplex containing N19 fragment (Figure 6B). Surprisingly, the binding activity of FXR1P towards p21 3’UTR-α fragment (nts 1–345) that contains a well...
characterized ARE sequence was null, being equal to the binding activity of the negative control N19Δ35. Also, p21 3'UTR-β fragment (nts 324–868) was not recognized by FXR1P. Interestingly, the most distal portion of p21 3'UTR, termed γ fragment (nts 851–1321), was specifically bound by FXR1P. These data indicate that FXR1P does not recognize p21 mRNA via the ARE motif present in the proximal portion of the 3'UTR (α fragment), but most likely via uncharacterized motif or sequence present in the distal portion of its 3'UTR-γ fragment.

Knowing that FXR1P interacted, at least in vitro, with p21 mRNA, we further sought to validate that this interaction occurs in vivo. To test this hypothesis, we isolated immunocomplexes containing FXR1P by performing UV-crosslinking and immunoprecipitation assays (CLIP, [32]). Immunoprecipitation of FXR1P mRNA complexes was carried out using the polyclonal antibody #830 against exon 16 of FXR1P present in all isoforms except the short ones [7,8] on C2C12 cell extracts (Figure 6C). Control CLIP was performed using non-immune rabbit IgGs. As expected, using the #3FX monoclonal antibody [7] against the constitutive exon 14 present in all isoforms of FXR1P, all the isoforms of FXR1P were detected in both inputs (Figure 6C, lane 1 and 2). Medium and long isoforms of FXR1P were selectively enriched in #830 immunoprecipitates (Figure 6C, Lane 4) and concomitantly depleted in #830 post-immunoprecipitation supernatant (Figure 6C, lane 6). The low amount of FXR1P small isoforms detected in the #830 immunoprecipitates most likely corresponds to the fraction of small isoforms interacting with FXR1P medium and long isoforms, since FXR1P is known to homodimerize [4]. In contrast, FXR1P is not recovered in immunoprecipitates obtained with control rabbit IgGs (Figure 6C, lane 3) and still present in the corresponding post-immunoprecipitation supernatant (Figure 6C, lane 5), confirming the specificity of the CLIP assay performed with #830 antibodies.

RT-PCR analysis of mRNAs extracted from both inputs and immunoprecipitates was then carried out (Figure 6D). The mRNA encoding p21, β-tubulin and the myogenic factors Myogenin and MyoD are detected in the input fractions (Figure 6D, lanes 1 and 2). Interestingly, only p21 mRNA was found selectively enriched in #830 immunoprecipitates (Figure 6D, lane 4) as compared to control immunoprecipitates (Figure 6D, lane 3), while Myogenin, MyoD and β-tubulin mRNAs were undetectable. This confirms the specificity of the approach and suggests that, in the C2C12 myoblastic cell line, endogenous p21 mRNA is present in mRNA complexes containing FXR1P.

The γ fragment of p21 3'UTR recognized by FXR1P has intrinsic stabilization properties

To elucidate the functional significance of FXR1P interaction with p21 3’UTR-γ fragment, we conducted luciferase assays on C2C12 cells expressing FXR1P normally (siControl-transfected) and inactivated for Fxr1 (siFxr1-transfected). The various portions of p21 3'UTR used for binding assays were cloned in the 3' of Renilla luciferase cDNA in a reporter system (Figure 7A). The influence of the 3' regulatory elements on Renilla mRNA and protein levels was then assessed, in the presence and in the absence of FXR1P, and compared to control vector without regulatory elements in the 3'UTR (Figure 7B, 7C). In the presence of FXR1P or when FXR1P is knocked-down, no significant difference to control is observed in the Renilla mRNA levels, when its cDNA is fused either to the proximal α or central β fragments of p21 mRNA 3'UTR. However, the distal γ fragment bound by FXR1P significantly increases Renilla mRNA levels in the presence of FXR1P (1.33-fold, Figure 7B); Intriguingly, removal of FXR1P by siRNA-mediated knockdown potentiated the mRNA stabilizing effect of the p21 3'UTR-γ fragment (1.76-fold; Figure 7B) compared to control. To assess whether variations of Renilla mRNA correlated to protein variations, we performed classical luminescence luciferase assays (Figure 7C). Interestingly, Fxr1 depletion lead to a significant increase in Renilla luciferase activity when its cDNA was either fused to the central β or distal γ fragment of p21 3'UTR (Figure 7C). However, the amplitude of variation was, again, higher when considering the γ fragment in siControl conditions (2.2-fold) or Fxr1 knockdown conditions (3.4-fold), compared to control empty vector. These data support the
hypothesis that FXR1P normally destabilizes p21 mRNA via binding to a motif present in the distal γ portion of its 3'UTR.

To test in vivo the hypothesis of FXR1P involvement in the control of endogenous p21 mRNA stability, we treated siControl- or siFxr1-transfected C2C12 cells with the transcription inhibitor actinomycin D (ActD), and measured the decay rate of p21 mRNA by quantitative RT-PCR. Interestingly, p21 mRNA appears to cycle rapidly in control myoblasts. Linear regression on semi-log values of p21 mRNA decay rate in siControl-transfected cells, provides an estimated half-life of 2.57 ± 0.14 hrs (Figure 7D), with only 16% mRNA remaining after 8 hrs. Conversely, upon Fxr1-depletion, p21 mRNA decay rate is strongly affected and its half-life is significantly increased, reaching 5.98 ± 0.42 hrs (p-val, 0.05). As a consequence, even after 8 hrs of ActD treatment, 43% of p21 mRNA is still present (Figure 7D). The slowing down of p21 mRNA decay following Fxr1-knockdown was further confirmed using 5,6-Dichlorobenzimidazole riboside (DRB), an adenosine analogue inhibiting mRNA synthesis (Figure S2). These data suggest that Fxr1-depletion increases endogenous p21 mRNA stability.

The γ fragment of p21 3’UTR contains a highly evolutionarily conserved G-quadruplex motif regulating its stability

The previous data support a negative role for FXR1P in the control of p21 mRNA stability via binding to the 561 nts long p21 3’UTR-γ portion. The next step was to determine the mRNA motif responsible for FXR1P recognition. So far, two mRNA motifs have been described to be recognized by FXR1P: the ARE motif of TNFa mRNA [20] and the G-quadruplex present in FMR1 mRNA [21]. Our in vitro data clearly indicate that the ARE motif present in the 3’UTR of p21 mRNA does not mediate the binding of FXR1P Isoe to p21 mRNA, so we therefore looked for the presence of putative G-quadruplex motifs in the γ fragment of p21 3’UTR. For this purpose, we used the QGRS weertool [33] that predicted three putative G-quadruplexes spread along the sequence of the γ fragment (Figure S3), and notably a high-score central G-quadruplex motif (nts 931–955). It is worth noticing that this high-score putative G-quadruplex is located within a 51 nts G-
rich region (position 918–955, 54% of G). To confirm the predicted G-quadruplex, we used the property of G-quadruplex forming regions to be detected by comparing reverse transcriptase elongation on RNA templates in the presence of either K\(^{+}\) or Na\(^{+}\). Indeed, stabilization of G-quadruplex structures by K\(^{+}\), but not by Li\(^{+}\) or Na\(^{+}\), results in cation-dependent pauses detectable on a sequence gel. The experiments were performed on the full-length 3’UTR and on the γ fragment alone and allowed us to identify two strong (position 939 and 940) and two weak G-quadruplex pauses (position 955 and 969) in the 3’UTR of p21 mRNA (Figure 8A). Both the full-length and the γ fragment exhibited the same pauses, indicating that the γ fragment retains the ability to form the G-quadruplex structure in a comparable manner to the full-length native 3’UTR (Figure 8A). Alignment of sequences corresponding to G-rich regions of p21 distal 3’UTR in mouse and human indicate high evolutionary conservation of this portion of non-coding sequences (Figure 8B) and argues in favour of its functional importance.

To explore the functional role of the G-quadruplex present in the 3’UTR of p21 mRNA, we constructed γ fragments mutants with partial (γΔ9) or full (γΔ38) deletion of the G-rich region containing the G-quadruplex (Figure 8C) that were cloned downstream of Renilla luciferase mRNA. Then, the levels of Renilla mRNA of the resulting constructs were assessed for each mutant in C2C12 cells. As previously shown in Figure 6B, the presence of the γ fragment did increase significantly the levels of Renilla mRNA, but partial or full deletion of the G-quadruplex potentiated the increase in the cognate mRNA levels (Figure 8D), mimicking the effect of Fsr1 knockdown in C2C12 cells (cf Figure 7B). These data argue in favour of a role of the G-quadruplex in mRNA stabilization that is potentiated by deletion of the binding site of FXR1P.

**Discussion**

Over the last decade, studies in Fsr1-knockout models have inferred that FXR1P plays a critical role in myogenesis [13,14,15]. However, even though FXR1P muscle-specific isoforms have unique RNA-binding properties [21], no specific mRNA targets and function have been identified so far for FXR1P in muscle. In this study, we have explored the functional consequences of the depletion of the FXR1P in myoblasts, with the purpose to understand its role in the early stage of myogenesis and in the cellular pathophysiology of FSHD, a human myopathy.
Figure 7. The γ portion of p21 mRNA 3’UTR modulates the stability of the mRNA that is potentiated by FXR1P depletion. (A) Scheme of the constructs bearing various portions of p21 mRNA 3’UTR (α, β and γ) used for luciferase assays. (B) Effect of p21 3’UTR –α, –β and –γ fragments on Renilla luciferase (Ren) mRNA levels in C2C12 cells transfected with control siRNAs (siControl) or siRNAs targeting Fxr1 (siFxr1). Quantitative RT-PCR analysis of the levels of Ren mRNA normalised to Firefly (Luc) mRNA relative to the empty construct are presented. In siControl cells, only the γ fragment significantly increased Ren mRNA levels, this effect is potentiated by Fxr1 depletion with siFxr1. In contrast, the α and β fragment have no effect on Ren mRNA levels, in the presence or absence of FXR1P. The results are presented as the means ± SEM of 4 experiments. (C) Effect of p21 3’UTR and its α, β and γ fragments on Renilla Luciferase activity in C2C12 cells transfected with control siRNAs (siControl) or siRNAs targeting Fxr1 (siFxr1). Results presented here represent the mean of the ratio of Luc-FL, Luc-α, Luc-β and Luc-γ to Luc-empty signal. In siControl cells, only the γ fragment significantly increased luciferase activity. In siFxr1 transfected cells compared to controls, the β and γ fragments increased luciferase activity, while the α fragment has no effect. However, the amplitude of variation is greater with the γ fragment and this effect is potentiated by Fxr1 depletion. Six independent experiments in triplicate for each transfection were quantified. For each transfection, Renilla was normalized to Firefly luciferase activity. RLU, relative luciferase units. (D) Fxr1-depletion increases the stability of endogenous p21 mRNA. C2C12 transfected with siControl (empty squares) or siFxr1 (black squares) were treated with the transcription inhibitor actinomycin D for 8 hrs. p21 mRNA levels were determined by quantitative RT-PCR at several time points and normalised to levels before treatment (t0). Percentage of remaining mRNA is plotted using a semi-log scale. Data presented represent the mean of n = 3 experiments. The asterisks * indicate p<0.05 of the Mann & Whitney test, while # and ## indicate respectively p<0.05 and p<0.01 of the Wilcoxon test.

doi:10.1371/journal.pgen.1003367.g007

Cellular pathways affected by Fxr1-depletion

Microarray analysis of our myoblastic model inactivated for Fxr1 enabled to show that FXR1P depletion affects the expression of a wide range of mRNA species that control several cellular pathways. One of the most represented functional categories correspond to ‘skeletal and muscular system development’ and ‘skeletal and muscular disorders’, in line with the evoked role of FXR1P in myogenesis and its altered pattern of expression in two human myopathies: FSHD [9] and DM1 [12]. Interestingly, the functional category ‘cell cycle’ appears also overrepresented in the affected functions, in particular, terms corresponding to ‘arrested in G0/G1 phase transition’ (related to the genes p21/Cdkn1a, HGF, IGF, IL6) actually reflect what we observed at the physiological level for Fxr1 inactivated myoblasts which remain blocked in the G0 phase, without undergoing further differentiation. Apart from p21, several mRNAs with altered levels in the absence of FXR1P seem to influence the functional categories affected and appear iteratively in our Ingenuity pathway analysis. These candidates for interaction with FXR1P in the context of myogenesis now deserve further investigation. Notably, Hepatocyte growth factor (Hgf) mRNA is significantly upregulated in the absence of FXR1P (Table S1, Figure 1E and 1F, Figure S1) and is known to play an essential role in the migration and proliferation of myogenic cells [34]. Similarly, the Insulin-like growth factor 1 (Igf1) would be a relevant target of FXR1P in the muscle context, since Igf1 plays a key regulatory role in skeletal muscle development, as well as muscle fiber regeneration and hypertrophy [35]. Finally, Cyclin-dependent kinase 15 (Cdk15) mRNA which, contrary to p21 mRNA, is downregulated in Fxr1-deficient myoblasts (Table S1, Figure 1E and 1F, Figure S1) would be an interesting candidate for regulation of cell-cycle progression by FXR1P. In this case, FXR1P would stabilize Cdk15 mRNA via recognition of a yet unknown specific motif. Murine and human Cdk15 mRNA are not annotated in the AREsite database [36] and therefore do not seem to bear a canonical AU-rich element sequence in their 3’UTR. However, analysis of the 3672 nts long human Cdk15 mRNA
using QGRS G-quadruplex mapping webtool reveals the presence of 8 putative G-quadruplex sequences (Table S3), with 2 putative G-quadruplex in the 3'UTR that represent binding sites for FXR1P. To ascertain the importance of FXR1P in the regulation of its putative mRNA targets newly identified in this study, it would be worth investigating the presence of ARE sequences, G-quadruplex RNA structures in their 3' untranslated region.

Role of FXR1P/G-quadruplex mRNA complex in the destabilization of p21 mRNA

Adequate regulation of the balance between proliferation and cell cycle arrest of myoblasts is a crucial step during myogenesis. The decision to progress through a new division cycle appears primarily regulated before the G1 to S phase transition, with p21 upregulation playing an important role in this process by blocking the formation of proliferation-inducing Cyclin A/Cdk2-E2F complexes [37]. In this context, p21 gene undergoes extensive regulation, both at the transcriptional and posttranscriptional level. Our data do not support a transcriptional mechanism for the maintenance of elevated p21 mRNA levels in Fxr1-deficient muscle cells. Indeed, in myoblasts, p21 is under the sole transcriptional control of the myogenic transcription factor MyoD that activates its promoter [38]. Our microarray and quantitative RT-PCR analyses reveal that MyoD levels remain normal in Fxr1-deficient myoblasts (Figure 1E). Finally, in luciferase assays, Ren mRNA levels are increased when p21 mRNA G-quadruplex region is fused to its 3'UTR, even though this mRNA does not contain the endogenous promoter of p21/Cdkn1a gene (Figure 7B, Figure 8D).

Figure 8. The γ portion of p21 mRNA 3'UTR contains an evolutionary conserved G-quadruplex structure with mRNA stabilization properties. (A) Cation-dependent termination of reverse transcription in the 3'-UTR full-length (FL) or γ fragment of p21 mRNA. Strong and weak pauses of reverse transcriptase (RT) are, respectively, indicated by large and thin arrows. Numbers correspond to positions of RT pauses, position +1 being the first nucleotide following the stop codon. (B) Localization and conservation of the G-quadruplex structure detected in (A) on the sequences of p21 3'UTR from Mus musculus (Mmu) and Homo sapiens (Hsa). (C) Scheme of the constructs used for luciferase assays bearing the conserved G-quadruplex of γ p21 mRNA (boxed) and two versions where the G-quadruplex has been deleted partially (Δ9) and fully (Δ38). (D) Effect of p21 3'UTR G-quadruplex and its deletions on Renilla luciferase (Ren) mRNA stability in C2C12 cells. Quantitative RT-PCR analysis of the levels of Ren mRNA normalised to Firefly (Luc) mRNA relative to the levels of the empty construct. The γ fragment bearing the G-quadruplex significantly increases Ren mRNA levels relative to empty vector. Partial or full deletion of the G-quadruplex sequence strongly increases Ren mRNA levels, both relative to empty vector and to the G-quadruplex bearing fragment. The results are presented as the mean of 4 experiments (±SEM). The asterisks * and # indicate p<0.05 respectively of the Wilcoxon test or of the Mann & Whitney test.

doi:10.1371/journal.pgen.1003367.g008
These evidences privilege an FXR1P-mediated posttranscriptional mechanism of regulation of p21 mRNA levels involving the binding of FXR1P.

In myoblasts, FXR1P long isoforms Isoe and Isof are most likely not playing a role in translational regulation, since they are detected in the nucleus and faintly in the cytoplasm but do not associate to polyribosomes [7,8,17,39]. On the other hand, we cannot exclude a mechanism involving translational inhibition via binding of small or medium isoforms of FXR1P to p21 mRNA to another motif, which may be located in the central part of p21 mRNA 3'UTR (β fragment) that activates translation in the absence of FXR1P (Figure 7A, 7B). This would be consistent with the previously described role of FXR1P small isoform Isoa in translational control [20]. However, our data strongly support the fact that the FXR1P-dependant translational control of p21 mRNA is mainly regulated by FXR1P long isoforms, notably Isoe, via binding to a 3'UTR-located G-quadruplex motif (Figure 8).

To date, the G-quadruplex has been described to be a negative [31,40] or positive [41] regulator of translation, and a zip-code for dendritic transport and synaptic localization [42] depending on its location on the mRNA (e.g. 5'UTR or 3'UTR) [for review see [43]). We report here an evolutionary conserved G-quadruplex motif as a novel RNA-binding motif present in a G-rich region of the distal portion of p21 mRNA 3'UTR. This motif, distinct from the classical ARE present in the proximal portion of the 3'UTR [30], appears nevertheless to control the stability of p21 mRNA.

Indeed, when fused to the 3'UTR of Renilla luciferase, the G-quadruplex induces an increase in Renilla mRNA levels, (Figure 7B, Figure 8D) and this effect is potentiated by deletion of the G-quadruplex (Figure 8D). Collectively, these data argue that the G-quadruplex of p21 mRNA 3'UTR participates in the control of mRNA stability via a mechanism involving FXR1P. A few reports describe the involvement of 3'UTR-located G-rich stretches as downstream sequence elements (DSE) promoting polyadenylation and leading to increased stability of mRNA when located downstream the polyadenylation site [44,45]. However, in the context of p21 mRNA, the G-quadruplex (position 918-955 nts) located upstream of p21 mRNA polyadenylation site (AAUAAA sequence in position 1309-1314 nts) could act as an upstream sequence elements (USE) promoting polyadenylation, as described for a U-rich sequence in *Pothorhumin* mRNA 3'UTR [46]. An alternate mechanism would involve that FXR1P long isoforms drive degradation of p21 mRNA via recruitment of microRNAs and the RISC complex. RNA interference is well described to occur in the cytoplasm, but it was recently shown that small non-coding RNAs can associate with complementary pre-mRNA target both in the nucleus and in the cytoplasm, by binding to Ago2 [47]. The latest is a key component of the RNA-Induced Silencing Complex (RISC) [47] and a well-known interactor of FXR1P in human cells [20], *Xenopus* oocytes [48], and in *Drosophila* [49,50]. Interestingly, p21 mRNA 3'UTR contains an evolutionarily conserved binding site for miR-22 100 nts upstream of the G-quadruplex motif (Figure S3). This microRNA was recently shown to regulate p21 mRNA levels [47] and is bound in *cvo* by Ago2 [51]. In this context, *Fxr1*-depletion or p21 3'UTR G-quadruplex deletion could prevent recruitment of the RISC complex on p21 mRNA and contribute to increase its stability, ultimately leading to an accumulation of p21 mRNA and of the cognate protein.

In myoblasts, Fxr1P is not the sole RNA-binding protein playing a key role in the regulation of p21 mRNA. Several reports demonstrate the importance of the proximal ARE of p21 mRNA 3'UTR- present in the α fragment- to control the stability of this mRNA. In myoblasts, the ARE-mediated stabilization of p21 mRNA is mediated by cooperative binding of HuR and hnRNPC1 [30,52], while its decay is controled by KSRP [53]. Members of the hnRNP family of proteins, PCBP1 and 2, control the central part of p21 3'UTR - the β fragment- [54]. Finally, another hnRNPE, PCBP4, binds and stabilizes the γ fragment [55], while we show in this study that binding of FXR1P to the G-quadruplex motif of p21 3'UTR-γ fragment destabilizes the mRNA. Here, we wish to propose a double system of regulation in which Fxr1P and PCBP4 cooperate to regulate the levels of p21 using the distal 3'UTR while HuR, RNPC1 and KSRP use the ARE in the proximal part. These complex regulatory systems enable a fine-tuning of p21 mRNA levels, and our data indicate a prominent role for Fxr1P as a modulator of p21 levels.

**Fxr1P control of p21 mRNA stability regulates myoblast cell-cycle exit**

We report that, when Fxr1P is depleted in the C2C12 cell line and in FSHD myoblasts, p21 mRNA levels increase (Figure 1, Figure 4). As a consequence, a subset of myoblasts becomes more permissive to cell cycle arrest, resulting in a reduced yield of myoblasts at each cycle of division (Figure 2, Figure 3). We also observed that the *Cyclin-dependent kinase 15 (Cdk15)* mRNA levels are decreased (Table S1; Figure 1E, 1F; Figure S1) it would be worth investigating whether its decreased levels also have an impact in this premature cell-cycle exit we observe in Fxr1-depleted myoblasts. Our data are in line with other studies in which overexpression of *p21* in myoblasts is sufficient to trigger cell cycle exit, even in mitogenic medium [28,56,57]. In our study, *p21* upregulation upon *Fxr1*-depletion causes cell cycle exit without onset of differentiation.

In conclusion, our study highlights for the first time the direct involvement of FXR1P Isoe in the control of p21 mRNA levels involving the binding of FXR1P to the G-quadruplex motif of p21 3'UTR-γ fragment. This allows to explain the reduced expression of p21 mRNA in FSHD myoblasts by FXR1P depletion. Our data are in line with other studies in which overexpression of FSHD myoblasts exhibited higher levels of p21 than controls, under normal growth conditions (this study and [38,59]). It is now tempting to speculate that depletion in FXR1P Isoe directly participates to the physiopathology of FSHD, by causing p21-mediated premature arrest of the cell cycle in FSHD myoblasts. Ultimately, this may limit the pool of myoblasts available for differentiation. This would directly contribute to explain the reduced muscularature detected in Fshr KO mice [13] and in *svf1*-knockdown *Xenopus* [14] at early stages of embryogenesis and development.

The fact that *p21* mRNA is an mRNA target for FXR1P Isoe has also crucial implications for the understanding of the pathophysiology of myopathies. Indeed, splicing defects of the *Fxr1* gene in FSHD myoblasts leads to reduced expression of the long FXR1P Isoe, the one that specifically binds p21 3'UTR. We and others have shown that FSHD myoblasts exhibited higher levels of p21 than controls, under normal growth conditions (this study and [38,59]). It is now tempting to speculate that depletion in FXR1P Isoe directly participates to the physiopathology of FSHD, by causing p21-mediated premature arrest of the cell cycle in FSHD myoblasts. Currently, this factor may limit the pool of myoblasts available for regeneration of muscle fibers, inducing progressive muscle wasting in FSHD patients. This hypothesis is supported by a study which demonstrates that p21 is essential for normal myogenic progenitor cell function in regenerating skeletal muscle [60]. A similar scenario may be envisioned in the case of the mouse model of DM1 in which reduced expression of FXR1P Isoe was determined [12].

**Conclusions**

In conclusion, our study highlights for the first time the direct involvement of an RNA-binding protein, Fxr1P, in a new...
pathway that regulates p21 levels to control myoblasts cell cycle exit. Perturbations of this pathway will have a strong impact in muscle development and implicate a new signal dependent on a 3′-UTR located G-quadruplex-RNA structure. In the future it will be important to explore the implications of FXR1P in pathophysiology of muscle disorders and the pleiotropic functions of FXR1P during myogenesis. Furthermore, our study opens new perspectives on the role of the other Fragile X related proteins in the control of cell cycle. Noteworthy, FMRP is known to recognize G-quadruplex mRNA structures and it would be tempting to control of cell cycle. Noteworthy, FMRP is known to recognize G-quadruplex mRNA structures and it would be tempting to speculate that FMRP could control p21-dependant cell cycle exit of neuronal progenitors during neurogenesis.

Materials and Methods

Cells

The C2C12 cell line, a subclone of the C2C4 murine myoblastic cell line [61,62], was cultivated under confluence state in the conditions described by ATCC. C2C12 cells were transfected with siRNA targeting exon 14 or exon 6 of Fxr1 mRNA (see Table S1) and/or constructs using the Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer’s protocol. Control experiments were performed using commercially available control random siRNA of matching GC content (Invitrogen). Transfected cells were always analysed 48 hrs post transfection. mRNA decay experiments were performed by adding actinomycin D (Act D, 5 μg/mL) or 5,6-Dichlorobenzimidazole riboside (DRB, 50 μM) to culture medium for 0 to 8 hrs.

Human myoblasts derived from muscle biopsies of n = 3 FSHD patients and n = 3 controls of matching age and gender were described in [9]. The procedures to generate myoblasts derived from human muscle biopsies were agreed by the French Health Authorities (AFSSAPS). Myoblasts cultures were established as previously described [9].

Gene expression profiling

Total RNA of C2C12 cells transfected with siFxr1 or siControl siRNAs was extracted using the RNeasy kit (Qiagen, Hilden, Germany). Integrity of RNA was assessed by using an Agilent BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA integrity of RNA was assessed by using an Agilent BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agilent Technologies) (RIN above 8). RNA samples were then labeled with Cy3 dye using the low RNA input BioAnalyser 2100 (Agil...
mRNA and containing a G-quadruplex forming structure) and N19A55 (N19 sequence in which the G-quadruplex is deleted) were cloned in pTL1 plasmid [31]. The various fragments from p21 cDNA were amplified by RT-PCR of C2C12 cDNAs and cloned in the pGemTEasy system (Promega) using the primers described in Table S1, as advised by the manufacturer. For filter binding assay, N19 or p21 constructs were in vitro transcribed using T7 RNA polymerase (Promega), the RNA products being labeled with [32P]-ATP. Labeled RNAs were purified on a 1% low-melting agarose gel (Ambion). Labeled RNAs (50,000 c.p.m., 4 fmol) were renatured for 10 min at 40°C in binding buffer (50 mM Tris–HCl (pH 7.4), 1 mM MgCl2, 1 mM DTT, 150 mM KCl, 1 mM DTT). In the presence of 2 U/mL of RNase inhibitors (RNasin, Invitrogen), 0.1 mg/mL of Escherichia coli total tRNA and 0.01% BSA, radiolabeled RNA were incubated to increasing amounts of FXR1P protein. RNA–protein complexes were allowed to form for 10 min on ice, filtered through MF-membranes (0.45 HA, Millipore) and washed with 2 mL binding buffer. Filters were air-dried and Cerenkov counting was used to assess the levels of remaining radioactivity on filters. Data were plotted as percentage of total RNA bound versus the protein concentration and one-site binding curve was drawn using the Prism 4 software.

UV-crosslinking and immunoprecipitation (CLIP)

To isolate mRNAs associated with FXR1P in vivo, UV-crosslinking and immunoprecipitations (CLIP) were performed with extracts of C2C12 cells using a protocol adapted from [63] and the #830 polyclonal antibody directed against the C-terminus of FXR1P [8]. For each assay, 10 μg of polyclonal antiserum was used to immunoprecipitate 25×10⁶ cells. An equivalent amount of unrelated rabbit IgGs (Sigma) were used as negative control. Approximately 1/20th of the homogenate and 1/4th of the immunoprecipitate were loaded on a 11% SDS–PAGE gel. Proteins transferred onto a 0.45 μm nitro-cellulose membrane were revealed using the 3FL antibody recognizing both FXR1P and FXR2P [8]. mRNAs were extracted from C2C12 input lysate and immunoprecipitates using Trizol reagent (Invitrogen) according to the manufacturer’s protocol and subjected to reverse transcription (RT) using the Superscript III RT-PCR system (Invitrogen). RT products were subjected to polymerase chain reaction (PCR), using a PCR Master Kit (Promega) and primers detailed in Table S4 specific for p21, Myogenin, MysD and β-Tubulin mouse cDNAs. The PCR program consisted in 10 min. of initial denaturation at 95°C followed by 35 cycles −30 s at 95°C, 30 s at 58°C, 30 s at 72°C and a final elongation step of 10 min at 72°C. PCR products were visualised on a 2% TAE agarose gel and amplicon size was verified using the 1 Kb+ DNA ladder (Invitrogen).

Luciferase assays

Luciferase assays were performed using the pSiCheck2 system (Promega) according to the manufacturer’s protocol. Briefly, the various fragments from p21-3’UTR cDNA (α, β and γ) were excised from the pGemTEasy vectors using the NotI site and inserted downstream of the Renilla luciferase cDNA using the NotI site of the pSiCheck2 vector. C2C12 cells were co-transfected in 96-well plates with the siRNA control or against Fxr1 and pSiCheck2 constructs. Luciferase assays were performed 48 hrs post transfection using the DualGlow Luciferase Kit (Promega) according to the manufacturer’s protocol.

Constructs

pTL1/FXR1-Hoe plasmid was cloned as described in [8]. The mutated version of this plasmid bearing 4 silent mutations in human Fxr1 cDNA that impede recognition by siFxr1#1 was produced by site-directed mutagenesis using primers described in Table S4 and the QuickChange kit (Stratagene).

Statistical analysis

To compare numerical data, non-parametric Mann & Whitney test was used for small sample size (n<30) and a Student T-test was used when n>30. Wilcoxon non-parametric tests were used to assess significance of Renilla luciferase mRNA or activity levels variations between each fragment relative to the empty vector (arbitrarily set to 1). All statistical analysis and data graphs were performed with the Prism 4 software. Only significant differences are displayed on the graphs.

Supporting Information

Figure S1 Confirmation of microarray mRNA candidates using a second siRNA targeting another constitutive exon of Fxr1 mRNA (exon 6). (A) Quantitative RT-PCR reveals a strong reduction of Fxr1 mRNA in C2C12 cells transfected with siRNA against Fxr1 (siFxr1#2) compared to siControl-transfected cells. (B) Western-blot analysis of untransfected (UT) and siFxr1-transfected cells (siFxr1#2) revealed with the antibody #3FX recognizing all isoforms of FXR1P reveals a strong depletion of all isoforms of FXR1P (short, medium and long) compared to control (siCtl), while the levels of FXR2P protein (asterisk, *) remain unchanged. β-tubulin (β-tub) signal is used to verify equal loading of lanes. (C) Quantitative-RT PCR analysis of a subset of mRNAs confirm that Sema7a, Mep2, Asg1, Cdkn1a/p21, Hgf, Dusp6 and Lhh mRNAs are significantly upregulated while Cdk15 mRNA is downregulated in Fxr1-depleted C2C12 myoblasts, confirming the microarray analysis and quantitative-RT PCR analysis using the first siFxr1 siRNA. Data are presented as means ± SEM of n = 4 experiments.

Figure S2 Confirmation that Fxr1-depletion increases the stability of endogenous p21 mRNA using a second transcription inhibitor. C2C12 transfected with siControl (empty squares) or siFxr1 (black squares) were treated with the transcription inhibitor 5,6-Dichlorobenzimidazole riboside (DRB) for 8 hrs. Percentages of remaining p21 mRNA at the various time points were determined by quantitative RT-PCR and normalised to levels before treatment (t0). During the first 5 hrs of treatment, p21 mRNA stability is clearly increased when Fxr1 transfection is knocked-down by siFxr1 transfection, as compared to siControl-transfected cells. At the dose used, DRB effect is reversible and transcription resumes after 5 hrs of treatment resulting in a progressive increase in p21 mRNA levels in both conditions.

Figure S3 Sequence analysis of p21 3’UTR γ fragment bound by FXR1P in search for G-quadruplexes and microRNA binding sites. The position and scores of the three putative G-quadruplexes structures predicted by the webtool QGRS [33] in the γ portion of murine p21 mRNA 3’UTR are boxed. The putative G-quadruplex located betweennts 931–955 displays a high score of 38 and lies within a G-rich region (nts 918–968) in which G are highlighted by empty circles (●). A conserved binding site for miR-22/22-3p conserved among species is located in position 837–843 nts, as predicted by TargetScan webtool.

Table S1 List of the 79 RefSeq annotated transcripts significantly modulated after Fxr1-depletion in myoblasts. NCBI RefSeq IDs give access to transcripts annotations. Logarithm (base 2) of
the average intensity (AvExp) and logarithm (base 2) of the ratio siFxr1/siControl are represented. The subset of miRNAs further validated in quantitative RT-PCR are highlighted in bold.

**Table S2** Ingenuity Pathway Analysis of microarray data to highlight selectively affected pathways in Fxr1-depleted myoblasts. All the affected pathways ordered by p-value are presented in (A), while pathways specifically related to ‘skeletal muscle’ or ‘cell cycle’ are respectively presented in (B) and (C).

**Table S3** Prediction of G-quadruplexes present in human CaK15 mRNA using QGRS webtool. G-quadruplexes displaying the highest scores are localized in the 5’UTR or coding sequence of the mRNA.

**Table S4** List of primers used in study.

**Acknowledgments**

The authors gratefully acknowledge Ms. Julie Cazareth and Dr. Frederic Braun (IPMC, CNRS UMR7275, Valbonne, France) for excellent technical support concerning FACS analysis and quantification of microscopic images. The authors are also grateful to the GDR G-quadruplex Network.

**Author Contributions**

Conceived and designed the experiments: LD PB BM SS HM BB. Performed the experiments: LD ND OK RT BM. Analyzed the data: LD OK BM HM PB BB. Contributed reagents/materials/analysis tools: SS. Wrote the paper: LD BB.

**References**

1. Khandjian EW (1999) Biology of the fragile X mental retardation protein, an RNA-binding protein. Biochem Cell Biol 77: 331–342.
2. Sutherland GR (1977) Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197: 265–266.
3. Coy JF, Settlebee Z, Bachner D, Hameister H, Joss S, et al. (1993) Highly conserved 3’ UTR and expression pattern of Fxr1 points to a divergent gene regulation of Fxr1 and Fmr1. Hum Mol Genet 4: 2209–2218.
4. Zhang Y, O’Connor JP, Sionmi MC, Stirnissen S, Dutra A, et al. (1995) The fragile X mental retardation syndrome protein interacts with novel homologs Fxr1 and Fxr2. Embo J 14: 5358–5366.
5. Penagarikano O, Mulle JJ, Warren ST (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8: 109–129.
6. Kirkpatrick LL, McIlwain KA, Nelson DL (1999) Alternative splicing in the fragile X mental retardation protein 1 isoforms are sequestered in the nucleus of undifferentiated myoblasts. BMC Genet 1: 1–4.
7. Khairian EW, Bardoni B, Corbin F, Sitterl A, Giroux S, et al. (1999) Novel isoforms of the fragile X related protein FXR1 are expressed during myogenesis. Hum Mol Genet 7: 2121–2130.
8. Davoli D, Sacconni S, Bechara ER, Delphane S, Allegre M, et al. (2008) Alteration of expression of muscle specific isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. J Med Genet 45: 679–695.
9. Davoli D, Huot ME, Khandjian EW (2005) Lost one, the Fragile X Mental Retardation protein is now back onto brain polyribosomes. RNA Biol 2: 1–3.
10. Bakker CE, de Diego Otero Y, Bontekoe C, Ragpoor P, Luteijn T, et al. (2000) Immunotoxicological and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res 258: 162–170.
11. Orrego JP, Chambon P, Metger D, Mouier DR, Snipes GJ, et al. (2000) Expanded CUG repeats in the DMMPK 3’UTR cause severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA 97: 2860–2865.
12. Mienjes EJ, Willemsen R, Kirkpatrick LL, Nieuwenhuizen IM, Hoogeveen-Westerveld M, et al. (2004) Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1 function in vivo. Hum Mol Genet 13: 1291–1302.
13. Huot ME, Bisson N, Davoli D, Mazroui R, Lavelle Y, et al. (2005) The RNA-binding protein fragile X-related 1 regulates somite formation in Xenopus laevis. Mol Cell 16: 4350–4361.
14. Van’t Padje S, Chaudhry B, Severijnen LA, van der Linde HC, Mientjes EJ, et al. (2009) Restriction in fragile X-related 1 protein causes cardiomyopathy and muscular dystrophy in zebrafish. J Exp Biol 212: 2564–2570.
15. Sotto MC, Nuusa R, Dreyfus G (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74: 291–298.
16. Tannini F, Bontekoe C, Bakker CE, van Uden L, Anar B, et al. (1999) Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet 8: 865–869.
17. Khandjian EW, Bechara ER, Davoli D, Bardoni B (2005) Fragile X Mental Retardation Protein: many partners and multiple targets for a promiscuous function. Current Genomics 6: 515–522.
18. Garnier J, Lachance C, Di Marco S, Hell Z, Marion D, et al. (2005) Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem 280: 5750–5763.
19. Vaesdeelen S, Stievt JA (2007) AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 128: 1105–1118.
20. Bechara ER, Davoli D, McSkol M, Bensaid M, Tremblay S, et al. (2007) Fragile X related protein 1 isoforms differentially modulate the affinity of fragile X mental retardation protein for G-quartet RNA structure. Nucleic Acids Res 35: 383–396.
21. Whitman SA, Cover C, Yu L, Nelson DL, Zarnescu DC, et al. (2011) Desmoplakin and talin2 are novel mRNA targets of fragile X-related protein-1 in cardiac muscle. Circ Res 109: 262–271.
22. Montarras D, Piment C, Chelly J, Kahn A, Gross F (1989) Expression of MyoD1 coincides with terminal differentiation in determined but inducible muscle cells. EMBO J 8: 2203–2207.
23. Watson PA, Hanauke-Abel HH, Flint A, Lalande M (1991) Minoxime reversibly arrests cell cycle progression at the G1-S phase border. Cytometry 12: 242–246.
24. Gong J, Tragano F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 311–317.
25. Kreipe H, Heidebrecht H, Hansen S, Rohlik W, Kubbe M, et al. (1993) A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142: 3–9.
26. Buckingham M (1994) Muscle differentiation. Which myogenic factors make muscle? Curr Biol 4: 61–63.
27. Helyes O, Novitch BG, Spencer DR, Skapek SX, Rhee J, et al. (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018–1021.
28. Sabourin LA, Rudnicki MA (2000) The molecular regulation of myogenesis. Clin Genet 57: 16–25.
29. van der Giessen K, Di Marco S, Clair E, Gallouzi IE (2005) RNAi-mediated HuR depletion leads to the inhibition of muscle cell differentiation. J Biol Chem 279: 47119–47126.
30. Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, et al. (2001) The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. Embo J 20: 4803–4813.
31. Ulbrich K, Jeune K, Mele A, Darrell RB (2005) CLIP: a method for identifying protein-RNA interaction sites in living cells. Methods 37: 376–386.
32. Kikumori S, D’Antuono L, Bagga PS (2006) QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res 34: W676–692.
33. Yamanese A, Ammano O, Sklavin HC (2003) Insulin-like growth factors, hepatocyte growth factor and transforming growth factor-alpha in mouse tongue myogenesis. Dev Growth Differ 45: 1–6.
34. Philippou A, Marsili M, Halapak S, Kostaliers M (2007) The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 43–54.
35. Gruber AR, Fallmann J, Kratochvil F, Kowarcz P, Hofacker IL (2011) AREst: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 39: D66–D69.
36. Puri PL, Balsamo C, Burio VL, Chirillo P, Natale G, et al. (1997) MysD prevents cyclinA/cdk2/ez2 complexes formation in terminally differentiated myocytes. Oncogene 14: 1171–1184.
37. Poleskaya A, Rudnicki MA (2002) A MyoD-dependent differentiation checkpoint: ensuring genome integrity. Dev Cell 3: 757–768.
38. Tamanini F, Khandjian LL, Schonkeren J, van Unen L, Bontekoe C, et al. (2000) The fragile X-related proteins FXR1 and FXR2 contain a functional AU-rich motif. Nucleic Acids Res 28: 435–444.
39. Kwan KY, Lam MM, Johnson MB, Dube U, Shim S, et al. (2012) Species-dependent posttranscriptional regulation of NOs1 by FMRP in the developing cerebral cortex. Cell 149: 899–911.

**Table S4** List of primers used in study.
42. Subramanian M, Rage F, Tabet R, Flatter E, Mandel JL, et al. (2011) G-quadruplex RNA structure as a signal for neurite mRNA targeting. EMBO Rep 12: 697–704.
43. Melko M, Bardoni B (2010) The role of G-quadruplex in RNA metabolism: involvement of FMRP and FMR2P. Biochimie 92: 919–926.
44. Kikin O, Zappala Z, D’Antonio L, Bagga PS (2008) GRSDB2 and GRS_UTRdb: databases of quadruplex forming G-rich sequences in pre-mRNAs and mRNAs. Nucleic Acids Res 36: D141–148.
45. Arhin GK, Booms M, Bagga PS, Milcarek C, Wilusz J (2002) Downstream sequence elements with different affinities for the hnRNP H/H’ protein influence the processing efficiency of mammalian polyadenylation signals. Nucleic Acids Res 30: 1042–1050.
46. Daubekswarth S, Kaufmann I, Gentzel M, Forstner KU, Gantzert AS, et al. (2007) Splicing factors stimulate polyadenylation via UNEs at non-canonical 3’ end formation signals. EMBO J 26: 2658–2669.
47. Gagnon KT, Corey DR (2012) Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. Nucleic Acid Ther 22: 1–16.
48. Mortensen RD, Serza M, Steitz JA, Vasudevan S (2011) Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA-protein complexes (microRNP). Proc Natl Acad Sci U S A 108: 4281–4286.
49. Caudy AA, Myers M, Hannon GJ, Hammond SM (2002) Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev 16: 2491–2496.
50. Ishizuka A, Siomi MC, Siomi H (2002) A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 16: 2497–2508.
51. Chi SW, Zang JB, Mele A, Darnell RB (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460: 879–86.
52. Cho SJ, Zhang J, Chen X (2010) RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res 38: 2256–2267.
53. Briata P, Forcales SV, Ponasi M, Corte G, Chen CY, et al. (2005) p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell 20: 891–903.
54. Waggoner SA, Johannes GJ, Liebhaber SA (2009) Depletion of the poly(C)-binding proteins alphaCP1 and alphaCP2 from K562 cells leads to p53-independent induction of cyclin-dependent kinase inhibitor (CDKN1A) and G1 arrest. J Biol Chem 284: 9039–9049.
55. Scoumanne A, Cho SJ, Zhang J, Chen X (2011) The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP2 via mRNA stability. Nucleic Acids Res 39: 213–224.
56. Kitzmann M, Fernandez A (2001) Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci 58: 571–579.
57. Guo K, Wang J, Andres V, Smith RC, Walsh K (1995) MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15: 3023–3029.
58. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, et al. (2003) Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 13: 322–333.
59. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R (2007) Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68: 569–577.
60. Havke TJ, Meesen AP, Jiang N, Graham S, Hutcheson K, et al. (2003) p21 is essential for normal myogenic progenitor cell function in regenerating skeletal muscle. Am J Physiol Cell Physiol 285: C1019–1027.
61. Yaffe D, Saxel O (1977) A myogenic cell line with altered serum requirements for differentiation. Differentiation 7: 159–166.
62. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silverstein L, et al. (1985) Plasticity of the differentiated state. Science 230: 758–766.
63. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
64. Davidovic L, Bechara E, Gravel M, Jaglin XH, Tremblay S, et al. (2006) The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol Genet 15: 1525–1538.
65. Davidovic L, Navrael V, Bonacorsu CM, Catania MV, Bardoni B, et al. (2011) A metabolic and systems biology perspective on the brain of the Fragile X syndrome mouse model. Genome Res 21: 2190–2202.